vimarsana.com

Latest Breaking News On - Bladder cancer program - Page 1 : vimarsana.com

AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial Cancer

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.

United statesJohns hopkins universityMax katesGenitourinary malignancies branchNational cancer instituteDrug administrationBladder cancer program at johns hopkins universityCancer researchClinical oncology genitourinary cancerBladder cancer sectionBacillus calmette guBladder cancer programBladder cancerAlignant bladder neoplasmUrothelial cancerAlignant neoplasia

Cancer Conundrum: Immune Checkpoint Inhibitor Use in Transplant Recipients

Randomized clinical trials of ICIs have traditionally excluded immunocompromised individuals, but emerging evidence suggests the drugs have the potential to treat advanced cancers in transplant recipients. Clinicians face a challenge in the use of immune checkpoint inhibitor therapy in organ transplant recipients because of their need for immunosuppression.

United statesNew yorkUniversity of washingtonPiyushk agarwalKenard jhaveriOrgan procurement transplantation networkBladder cancer programSociety of urologic oncologyDrug administrationUniversity of chicagoZucker school of medicine at hofstra northwellKidney internationalJournal of the national comprehensive cancer networkInternational journal of cancerUrologic oncologyZucker school

UroGen Pharma - New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO in the Treatment of UTUC of the Ureter and Renal Pelvis

PRINCTON - UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a. | May 1, 2023

United statesMark schoenbergJoseph jacobUrogen rtgelBladder cancer programAmerican urological association meetingUrogen pharma ltdExchange commissionGen pharmaFirst analysisUreteral tumorsMedical universityChief medical officerPrivate securities litigation reform actRisk factorsStates securities

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis. | April 30, 2023

United statesJoseph jacobUrogen pharmaMark schoenbergUrogen pharma ltdAmerican urological association meetingBladder cancer programNephrostomy administrationDrug administrationFirst analysisUreteral tumorsUpstate medical universityChief medical officerUpper tract urothelial cancerPrescribing informationPatient information

vimarsana © 2020. All Rights Reserved.